447.95
+25.75
+(6.10%)
As of 5:25:18 PM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
10,625,800.00
9,869,200.00
8,930,700.00
7,574,400.00
6,205,700.00
Cost of Revenue
1,475,100.00
1,262,200.00
1,080,300.00
904,200.00
736,300.00
Gross Profit
9,150,700.00
8,607,000.00
7,850,400.00
6,670,200.00
5,469,400.00
Operating Expense
4,912,000.00
4,299,500.00
3,485,000.00
2,777,900.00
2,600,000.00
Operating Income
4,238,700.00
4,307,500.00
4,365,400.00
3,892,300.00
2,869,400.00
Net Non Operating Interest Income Expense
611,000.00
570,600.00
89,800.00
-56,600.00
-36,000.00
Other Income Expense
-4,590,100.00
-498,300.00
-222,800.00
-1,105,300.00
283,500.00
Pretax Income
259,600.00
4,379,800.00
4,232,400.00
2,730,400.00
3,116,900.00
Tax Provision
739,400.00
760,200.00
910,400.00
388,300.00
405,200.00
Net Income Common Stockholders
-479,800.00
3,619,600.00
3,322,000.00
2,342,100.00
2,711,700.00
Diluted NI Available to Com Stockholders
-479,800.00
3,619,600.00
3,322,000.00
2,342,100.00
2,711,700.00
Basic EPS
-1.85
14.05
12.97
9.09
10.44
Diluted EPS
-1.90
13.89
12.82
9.01
10.29
Basic Average Shares
258,000.00
257,700.00
256,100.00
257,700.00
259,841.00
Diluted Average Shares
258,775.00
260,500.00
259,100.00
259,900.00
263,396.00
Total Operating Income as Reported
-270,400.00
3,832,000.00
4,307,400.00
2,782,100.00
2,856,300.00
Total Expenses
6,387,100.00
5,561,700.00
4,565,300.00
3,682,100.00
3,336,300.00
Net Income from Continuing & Discontinued Operation
-479,800.00
3,619,600.00
3,322,000.00
2,342,100.00
2,711,700.00
Normalized Income
3,082,389.00
4,012,363.00
3,367,530.00
3,294,651.60
2,723,097.00
Interest Income
649,400.00
614,700.00
144,600.00
4,900.00
22,200.00
Interest Expense
38,400.00
44,100.00
54,800.00
61,500.00
58,200.00
Net Interest Income
611,000.00
570,600.00
89,800.00
-56,600.00
-36,000.00
EBIT
298,000.00
4,423,900.00
4,287,200.00
2,791,900.00
3,175,100.00
EBITDA
517,700.00
4,605,200.00
4,435,500.00
2,917,500.00
3,284,600.00
Reconciled Cost of Revenue
1,475,100.00
1,262,200.00
1,080,300.00
904,200.00
736,300.00
Reconciled Depreciation
219,700.00
181,300.00
148,300.00
125,600.00
109,500.00
Net Income from Continuing Operation Net Minority Interest
-479,800.00
3,619,600.00
3,322,000.00
2,342,100.00
2,711,700.00
Total Unusual Items Excluding Goodwill
-4,509,100.00
-475,500.00
-58,000.00
-1,110,200.00
-13,100.00
Total Unusual Items
-4,509,100.00
-475,500.00
-58,000.00
-1,110,200.00
-13,100.00
Normalized EBITDA
5,026,800.00
5,080,700.00
4,493,500.00
4,027,700.00
3,297,700.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-946,911.00
-82,737.00
-12,470.00
-157,648.40
-1,703.00
12/31/2020 - 6/29/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2H51.HM Ocugen Inc
0.7185
+1.27%
T9G.SG Vidac Pharma Holding Plc
0.6350
-3.79%
2H51.MU Ocugen Inc
0.7490
+7.00%
NP5.DE Newron Pharmaceuticals S.p.A.
10.18
+3.14%
1VT.F Viking Therapeutics, Inc.
32.03
-0.22%
ROVI.MC Laboratorios Farmaceuticos Rovi, S.A.
65.55
+0.08%
ADIL Adial Pharmaceuticals, Inc.
0.8050
-3.01%
DAWN Day One Biopharmaceuticals, Inc.
12.39
-3.65%
VINC Vincerx Pharma, Inc.
1.5200
+1.33%
BNTX BioNTech SE
122.09
+1.00%